Tysabri - He said he expects Tysabri to return in the third quarter and that it will be re-launched on a country by country basis, to start with Germa
Elan confident on revenues from Tysabri
RTE.ie - Ireland
Elan has posted a smaller than expected first quarter loss of $0.08 per share, and said it was confident revenues form its Tysabri drug would accelerate a ...
Elan 1Q Loss Narrows, Tysabri To Boost Stock
newratings.com - USA
Elan CEO Kelly Martin says he expects to "build momentum as we move through the year." Goodbody Stockbrokers adds, "Once Tysabri is back on the market ...
Elan reports fall in quarterly loss; Revenues from Tysabri ...
FinFacts Ireland - Ireland
... drugs firm Elan has reported a smaller than expected first quarter loss of $0.08 per share, and said it was confident revenues from its Tysabri drug would ...
Elan reaffirms Tysabri commitment
Irish Examiner - Cork,Ireland
Pharmaceutical company Elan has forecast a €150m-€175m full-year before-tax loss, excluding revenues from its suspended MS drug Tysabri. ...
posted by Bill at 1:33 AM
0 Comments:
Post a Comment
<< Home